Multiple Sclerosis Spastic Pain Relief Secondary to Medicinal Marijuana

Eric J. Basile^{1, 2,} , Aaron Campeas¹, Omar Rafa¹ and Autumn Breutzmann¹

¹Touro College of Osteopathic Medicine, NY, New York, United States

²Holy Name Medical Center, Teaneck, NJ, United States

Cite this paper:
Eric J. Basile, Aaron Campeas, Omar Rafa and Autumn Breutzmann. Multiple Sclerosis Spastic Pain Relief Secondary to Medicinal Marijuana. American Journal of Medical Case Reports. 2021; 9(6):339-341. doi: 10.12691/ajmcr-9-6-9

Abstract

A 57-year-old male presented to an outpatient Multiple Sclerosis (MS) clinic for excruciating spastic pain secondary to MS. After a trial of multiple pain management drugs with no success, he began a trial of marijuana. In this paper, we report the extent of improvement in quality of life secondary to cannabinoid use after failing multimodal pain management regimens.

Keywords:
multiple sclerosis pain management medicinal marijuana cannabinoids

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Wallin, Mitchell T., et al. “The Prevalence of MS in the United States.” Neurology, vol. 92, no. 10, 2019,
[2]	Hill, Kevin P. “Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems.” Jama, vol. 313, no. 24, 2015, p. 2474.
[3]	“Stem Cell Therapy and MS.” Bioeden US, The Multiple Sclerosis Foundation, 17 May 2018, www.bioeden.com/us/treatment/stem-cell-therapy-ms/.
[4]	Truini, A, et al. “A Mechanism-Based Classification of Pain in Multiple Sclerosis.” Journal of Neurology, Springer-Verlag, Feb. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3566383/.
[5]	Hugos CL, Cameron MH. Assessment and Measurement of Spasticity in MS: State of the Evidence. Curr Neurol Neurosci Rep. 2019 Aug 30; 19(10): 79.
[6]	Vijayasingham L, Mairami FF. Employment of patients with multiple sclerosis: the influence of psychosocial-structural coping and context. Degener Neurol Neuromuscul Dis. 2018 Mar 26; 8: 15-24.
[7]	Coyne KS, Boscoe AN, Currie BM, Landrian AS, Wandstrat TL. Understanding Drivers of Employment Changes in a Multiple Sclerosis Population. Int J MS Care. 2015 Sep-Oct; 17(5): 245-52.
[8]	Schabas, A., Vukojevic, V., Taylor, C., Thu, Z., Badyal, A., Chan, J., Carruthers, R. (2019). Cannabis-based product use in a multiple sclerosis cohort. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5(3), 205521731986936.
[9]	Rice, Jessica, and Michelle Cameron. “Cannabinoids for Treatment of MS Symptoms: State of the Evidence.” Current Neurology and Neuroscience Reports, U.S. National Library of Medicine, 19 June 2018, www.ncbi.nlm.nih.gov/pubmed/29923025.